Navigation Links
Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine

GENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharmaceuticals announced today the successful completion of a Phase IIa proof of concept trial with its lead compound ADX10059 in patients with migraine. The study achieved its primary objective, the absence of pain at 2 hours after dosing, with statistical significance, and also showed trends towards improvement in pain-free status and improvement of migraine pain at other time points. ADX10059 has already recently demonstrated a potential therapeutic benefit in a Phase IIa study in gastro-esophageal reflux disease (GERD), and is currently completing a Phase IIa study in anxiety.

ADX10059 is a potent, selective, negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5 NAM). Various pre-clinical pharmacology experiments have shown that glutamate is largely responsible for signal transmission in the neural circuit involved in migraine, and mGluR5 receptors are found at strategic points along the pathway. Inhibition of mGluR5 might therefore prevent the initiation of the migraine circuit, or interrupt it once established. For this initial exploratory study on the utility of an mGluR5 NAM in the management of migraine, an acute treatment paradigm was used.

The study was conducted in 129 migraine patients at opinion leader sites in the UK and Germany, according to the gold-standard design used for acute treatment of migraine. It comprised a multi-centre, double-blind, placebo-controlled comparison of a single dose of ADX10059 with placebo, to treat a single moderate or severe (IHS Grade 2 or 3) migraine headache, in an outpatient setting. Standard efficacy outcomes were used, with the primary efficacy variable being the proportion of patients pain-free (IHS Grade 0) 2 hours after dosing.

ADX10059 met the primary endpoint, showing a statistically significant higher number of patients pain-free 2 hours after dosing compared to placeb
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final recognition ... Contact Lens Health Week, 1-800 Contacts is sharing how ... that contact lens wearers who do not properly care ... for eye infections. Most contact lens ... but a clean lens case is sometimes overlooked.  When ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... 23, 2011 A recently enacted standard has replaced ...  This superseding standard, the Statement on Standards for Attestation ... 15, 2011 and pushes service organizations to enforce a ... (Logo: http://photos.prnewswire.com/prnh/20080206/AQW030LOGO-b ) Rising ...
... 23, 2011 Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... presenting at the Jefferies 2011 Global Healthcare Conference in ... Officer of Unilife, is scheduled to present at 5:00 ... Wednesday, September 28, 2011. The conference presentation ...
Cached Medicine Technology:Rising Medical Solutions, an Early Adopter of SAS 70's Replacement Standard 2Rising Medical Solutions, an Early Adopter of SAS 70's Replacement Standard 3Unilife to Present at the Jefferies 2011 Global Healthcare Conference in London 2
(Date:8/29/2015)... , ... August 29, 2015 , ... ProDrop Particles includes ... Each preset contains 15 seconds of unique footage that users can shrink and stretch ... zoom, attract and more. Users can customize color, brightness, scale, speed, range, and flare ...
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining ... County Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage ... their outpatient wound center. , Transitioning wound care management providers can be ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing ... their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart ... They believe that together, a difference can be made. Walkers can participate in the ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2
... Award-winning car toys offer schools innovative teaching tool ... RANDOLPH, Mass., July 20 May Institute, the National Autism ... for Classrooms," a unique summer charitable campaign created to donate innovative ... Automoblox, the retro-modern, mix-and-match car design system, has won major awards ...
... , Teamsters File Charge ... Waste into Open Refuse Dumpsters , , ... the Environmental Investigations Division of the City of St. Louis today charging American ... , The complaint was filed after red biohazard bags ...
... , Statement by ... Homecare , , ARLINGTON, Va., ... healthcare system, the Obama administration and Members of Congress have been ... provides medical oxygen, respiratory therapy, hospital beds, wheelchairs, walkers and other ...
... , , , , ... a higher risk for heart disease, stroke, and ... percent of the U.S. population is living without dental insurance - nearly ... , To help make dental care more accessible to people, ...
... H1N1 swine flu vaccine, which should be ready by fall ... and Drug Administration has approved the vaccine to protect against ... agency noted that this vaccine will not protect people from ... around the world and is expected to return to the ...
... in processed foods, experts advise reading food labels , MONDAY, ... diet contribute to hypertension, but it can also reduce the ... "What is striking about these results is the degree of ... medicine at the University of Alabama at Birmingham, and a ...
Cached Medicine News:Health News:May Institute, National Autism Center, and Automoblox Launch 'Cars for Classrooms' Summer Charitable Campaign to Benefit Children with Autism 2Health News:May Institute, National Autism Center, and Automoblox Launch 'Cars for Classrooms' Summer Charitable Campaign to Benefit Children with Autism 3Health News:May Institute, National Autism Center, and Automoblox Launch 'Cars for Classrooms' Summer Charitable Campaign to Benefit Children with Autism 4Health News:Congress Must Recognize Homecare as Cost-Effective Part of Health Care Reform 2Health News:Congress Must Recognize Homecare as Cost-Effective Part of Health Care Reform 3Health News:More Americans Have Cell Phones Than Dental Coverage 2Health News:FDA Approves Seasonal Flu Vaccine for 2009-2010 2Health News:FDA Approves Seasonal Flu Vaccine for 2009-2010 3Health News:High-Salt Diet Dampens Effects of Blood Pressure Drugs 2Health News:High-Salt Diet Dampens Effects of Blood Pressure Drugs 3
... its synthetic bone substitute Ossatura. Developed at Isotis, ... material, i.e. a material that is designed to ... the musculo-skeletal system that results in bone growth. ... and reduces in part or entirely the need ...
Schuknecht-Weitlaner retractor, sharp, angled arms....
Beckman-Weitlaner retractor, blunt, with hinged arms, 6 1/2"....
Daubenspeck sharp curette, 8....
Medicine Products: